SPOTLIGHT: Gilead, Achillion axe hep C project


Gilead Sciences and Achillion are axing a joint development program for an experimental hepatitis C therapy after GS 9132 demonstrated an increased risk of kidney failure in an early/mid-stage trial. Researchers were concerned by signs of an increase in serum creatinine levels in volunteers, though they said the increases were reversible after dosing. Both companies, however, added that they would continue to focus on other NS4A antagonists after seeing positive data on efficacy. Release | Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.